857134P
Avanti
18:1 Hemi BMP (S,R)
sn-(3-oleoyl-2-hydroxy)-glycerol-1-phospho-sn-3′-(1′,2′-dioleoyl)-glycerol (ammonium salt), powder
Synonym(s):
110734
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
C60H114NO11P
CAS Number:
Molecular Weight:
1056.52
UNSPSC Code:
51191904
NACRES:
NA.25
Recommended Products
![18:1 BDP (S,S) sn-[2,3-dioleoyl]-glycerol-1-phospho-sn-1′-[2′,3′-dioleoyl]-glycerol (ammonium salt), powder](/deepweb/assets/sigmaaldrich/product/structures/968/508/ef30cef0-7343-47f1-8394-69c4cd0769d0/640/ef30cef0-7343-47f1-8394-69c4cd0769d0.png)
Assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 5 mg (857134P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 857134P
lipid type
phospholipids
cardiolipins
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@@](COP(OC[C@@]([H])(O)COC(CCCCCCC/C=C\CCCCCCCC)=O)([O-])=O)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O.[NH4+]
General description
Hemi-bis(monoacylglycero)phosphate (hemi-BMP) is an anionic lipid, comprising a glycerophosphoglycerol backbone in which three fatty acyl chains are esterified to the glycerol hydroxyls.
Application
18:1 Hemi BMP (S,R) may be used in the preparation of selective organ targeting (SORT) lipid nanoparticles (LNPs) for the selective mRNA delivery to the spleen.
Packaging
5 mL Clear Glass Sealed Ampule (857134P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hemi-bis (monoacylglycero) phosphate composition and biosynthesis in Escherichia coli
Garrett TA and Rose RL
Faseb Journal (2010)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service